Pharmacological studies of Trelagliptin
Trelagliptin (Trelagliptin) is a new once-weekly antidiabetic medication that improves compliance in patients with type 2 diabetes. A report demonstrating the efficacy and safety of once-weekly trotagliptin, a DPP-4 inhibitor, in combination with insulin therapy. In patients with inadequate glycemic control, trotagliptin 100 mg once weekly plus combined insulin significantly reduced HbA1c at the end of the double-blind period despite the use of insulin preparations and diet and exercise therapy (P < .0001 compared with the P/a group).

Tretagliptin is mainly excreted through the kidneys. A single dosePharmacokinetics (PK) study of 50 mg trolagliptin in non-Japanese CKD patients showed mild renal impairment (creatinine clearance[Ccr]>50 to ≤80 mL/min), patients with moderate renal impairment (Ccr≥30 to ≤50 mL/min) increased by 105.7%, and patients with severe renal impairment (Ccr<30) increased by 55.7% compared with healthy (Ccr>80 mL/min) adults. mL/min, but not on hemodialysis) and 268.1% of ESRD patients on hemodialysis, thus indicating increased trotagliptin n exposure. Based on these data, patients with mild RI do not need to adjust the dose of trolagliptin, but patients with moderate renal function need to reduce it to half the standard dose (50 mg/week).
The original drug of trotagliptin has not yet received relevant approval for marketing in China, so it cannot be covered by medical insurance. Currently, the price of trotagliptin original drug, specification 50mg*20 tablets per box, which is currently on the market overseas, may be around RMB 1,000 (the price may fluctuate due to exchange rates). There are also generic Trelagliptin drugs produced in other countries, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 100mg*21 tablets produced by a Bangladesh pharmaceutical factory may be several hundred yuan per box (the price may fluctuate due to exchange rates). For more drug information and specific prices, please consult Yaode Medical Consultant.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)